Publication | Closed Access

Phase II evaluation of LY2603618, a first-generation CHK1 inhibitor, in combination with pemetrexed in patients with advanced or metastatic non-small cell lung cancer

Phase Ii EvaluationOncologyMedicineFirst-generation Chk1 InhibitorImmune Checkpoint InhibitorCancer TreatmentPharmacologyRadiation OncologyLung Cancer